David Boulton
David Boulton
Clinical Pharmacology & Quantitative Pharmacology, R&D, AstraZeneca
Verified email at
Cited by
Cited by
Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects
B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, ...
Clinical Pharmacology & Therapeutics 85 (5), 520-526, 2009
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton
Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
RA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ...
Diabetes care 36 (10), 3169-3176, 2013
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics
DW Boulton, CL DeVane, HL Liston, JS Markowitz
Life sciences 71 (2), 163-169, 2002
Extensive binding of the bioflavonoid quercetin to human plasma proteins
DW Boulton, UK Walle, T Walle
Journal of Pharmacy and Pharmacology 50 (2), 243-249, 1998
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2
S Kasichayanula, X Liu, F LaCreta, SC Griffen, DW Boulton
Clinical pharmacokinetics 53, 17-27, 2014
Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers
JS Markowitz, CL DeVane, DW Boulton, SW Carson, Z Nahas, SC Risch
Life sciences 66 (9), PL133-PL139, 2000
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism
DW Boulton, UK Walle, T Walle
Journal of pharmacy and pharmacology 51 (3), 353-359, 1999
Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ...
Circulation 142 (11), 1040-1054, 2020
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
S Kasichayanula, X Liu, M Pe Benito, M Yao, M Pfister, FP LaCreta, ...
British journal of clinical pharmacology 76 (3), 432-444, 2013
Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections
A Fura, A Khanna, V Vyas, B Koplowitz, SY Chang, C Caporuscio, ...
Drug metabolism and disposition 37 (6), 1164-1171, 2009
Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
CS Wilcox, W Shen, DW Boulton, BR Leslie, SC Griffen
Journal of the American Heart Association 7 (4), e007046, 2018
Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin
D Boulton, L Li, EU Frevert, A Tang, L Castaneda, NN Vachharajani, ...
Clinical pharmacokinetics 50, 253-265, 2011
Enantioselective disposition of salbutamol in man following oral and intravenous administration
DW Boulton, JP Fawcett
British journal of clinical pharmacology 41 (1), 35-40, 1996
Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol
JS Markowitz, CL DeVane, DW Boulton, Z Nahas, SC Risch, F Diamond, ...
Drug Metabolism and Disposition 28 (6), 620-624, 2000
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 …
S Kasichayanula, M Chang, M Hasegawa, X Liu, N Yamahira, FP LaCreta, ...
Diabetes, Obesity and Metabolism 13 (4), 357-365, 2011
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy …
S Kasichayanula, X Liu, WC Shyu, W Zhang, M Pfister, SC Griffen, T Li, ...
Diabetes, Obesity and Metabolism 13 (1), 47-54, 2011
Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate
DW Boulton, P Arnaud, CL DeVane
Clinical Pharmacology & Therapeutics 70 (1), 48-57, 2001
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study
S Kasichayanula, X Liu, W Zhang, M Pfister, FP LaCreta, DW Boulton
Clinical therapeutics 33 (11), 1798-1808, 2011
The system can't perform the operation now. Try again later.
Articles 1–20